<DOC>
	<DOC>NCT02817633</DOC>
	<brief_summary>This is a multicenter, open-label, first-in-human Phase 1 study evaluating the anti-TIM-3 (T cell immunoglobulin and mucin containing protein-3) antibody TSR-022, as a monotherapy and in combination with an anti-PD-1 antibody, in patients with advanced solid tumors who have limited available treatment options. The study will be conducted in 2 parts: dose escalation and cohort expansion.</brief_summary>
	<brief_title>A Phase 1 Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Partial Patient with advanced or metastatic solid tumor and has disease progression or treatment intolerance after treatment with available therapies Agreement to biopsies before and during treatment, depending on study part Female patients must have a negative serum pregnancy test or be of nonchildbearing potential. Two methods of contraception required for males and females of childbearing potential Eastern Cooperative Oncology Group (ECOG) performance status of â‰¤ 1 and adequate organ function Partial Received prior therapy with an antiCTLA4, antiPD1, antiPD1ligand1 (antiPDL1), or antiPD1 ligand2 (antiPDL2) agent within 8 weeks prior to initiation of study treatment depending on study part Known uncontrolled central nervous system (CNS) metastases and/or carcinomatous meningitis or known malignancy that progressed or required active treatment within the last 2 years Pregnant, breastfeeding, or expecting to conceive children within projected duration of study History of human immunodeficiency virus (HIV), interstitial lung disease, active Hepatitis B or Hepatitis C Autoimmune disease that required systemic treatment in past 2 years Not recovered from radiation and chemotherapyinduced AEs or received blood transfusion Participated in another investigational study (drug or device) within 4 weeks of first dose Received prior anticancer therapy within 21 days of first dose Not recovered from AEs and/or complications from major surgery prior to first dose Received a vaccine within 7 days of first dose</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Anitibodies</keyword>
	<keyword>TSR-022</keyword>
	<keyword>Advanced solid tumors</keyword>
	<keyword>Metastatic solid tumors</keyword>
	<keyword>Immunotherapy</keyword>
	<keyword>PD-1</keyword>
	<keyword>Anti-PD-1</keyword>
	<keyword>colorectal cancer</keyword>
	<keyword>non-small cell lung cancer</keyword>
	<keyword>Melanoma</keyword>
	<keyword>Nivolumab</keyword>
</DOC>